Yatscoff to speak in NYIsotechnika invited to participate in focus session at BIO CEO & Investor conference
14:05 EST Tuesday, February 22, 2005
EDMONTON, Feb. 22 /CNW/ - Isotechnika Inc. announced today that Dr. Randall Yatscoff, the Company's President and Chief Operating Officer has been invited to participate in a panel discussion about autoimmune diseases at the BIO CEO & Investor conference in New York. The focus session entitled "Fighting the Enemy Within: Psoriasis, RA and Lupus" will take place on Wednesday, February 23rd at 9:30 a.m. Eastern Time in the Duke of Windsor room at the Waldorf Astoria hotel. The focus session is intended to provide investors with a comprehensive overview of the clinical developments and opportunities in the autoimmune area.
"This conference gives our Company an excellent opportunity to highlight the significant developments in our Phase III Canadian clinical trial program that is now fully enrolled. Further, this will offer the forum for us to have one on one interactions with several key investment firms in the U.S.," stated Dr. Randall Yatscoff, Isotechnika's President and Chief Operating Officer.
The slides presented by Dr. Yatscoff will be posted to the Company's corporate Web site at www.isotechnika.com in conjunction with the focus session on Wednesday, February 23, 2005 at 9:30 a.m. EST. Interested parties are also encouraged to visit BIO's conference website at www.ceo.bio.org to access a web cast of the panel discussion. The web cast will be available starting on Thursday, February 24 and archived for 90 days.
About Isotechnika Inc.
---------------------
Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in medicinal chemistry and immunology, the Company is focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Its entrepreneurial management and world-class team of scientists are building a pipeline of immunosuppressive drug candidates for treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. Isotechnika looks to become the leader in development of immunosuppressant therapies.
Isotechnika's lead drug, ISA247, presently referred to as trans-ISA247, is an immunosuppressant that has successfully completed a Phase II trial for psoriasis and Phase IIa trial for kidney transplantation. The Company also has two additional immunosuppressive compounds in its drug pipeline, TAFA93 and TKB662. Both compounds are in early stage clinical development, Phase I and pre-clinical respectively.
In addition to the Company's drug pipeline, Isotechnika also has a diagnostic division, which includes the Helikit(TM) and Diatest(TM) breath kits. The Helikit(TM), a 13C breath test is used for the detection of H.pylori, a bacterium that infects a large portion of the population. The Diatest(TM), a (13)C glucose breath test is used to measure insulin resistance.